Back to discover
Disease

Essential Hypertension

Late-stage therapeutic developmentEmerging research
MeSHEssential Hypertension
1
Publications
22
Clinical trials
12
Associated genes
9
Related proteins
2017
Latest publication
Current focus
Proto-oncogene mas biologyRenin biologyTherapeutic development
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
Clinical Milestones8View
Results expected 4
Other updates 4
Regulatory Updates2View
  • 2026-05-04Product authorisation ended — TelmisartanHypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage.
  • 2026-04-30Product authorisation ended — TelmisartanHypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage.
Activity timeline10

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Telmisartanapproved

Product authorisation ended — Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Red… (2026)

Spironolactoneapproved

Original application approval — In the management of refractory oedema associated with congestive cardiac failure; hepati… (2023)

Azilsartan medoxomilapproved

Original application approval — Edarbi is indicated for the treatment of essential hypertension in adults. (2011)

Irbesartanapproved

Generic approval — Treatment of essential hypertension. Treatment of renal disease in patients with hyperten… (2009)

Aliskirenapproved

Original application approval — Treatment of essential hypertension. (2007)

Clinical trials

13 sponsors · 4 new · 0 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
22
All trials
5
Active
16
Late-stage
5
Completed
Late-stage studies

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)

Phase 3 · Recruiting · Liquidia Technologies, Inc.

Comparison of Initial Dual Oral COMbination Therapy to MOnotherapy in Pulmonary Arterial Hypertension With Cardiovascular comorbiDITIES

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease

Phase 3 · Active, not recruiting · Liquidia Technologies, Inc.

Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension: a Randomized, Double-blind, Placebo-controlled Trial

Phase 4 · Recruiting · Beijing Anzhen Hospital

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Phase 3 · Recruiting · Inhibikase Therapeutics

A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients

Phase 4 · Completed · Boryung Pharmaceutical Co., Ltd
Recruiting

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)

Phase 3 · Recruiting · Liquidia Technologies, Inc.

Comparison of Initial Dual Oral COMbination Therapy to MOnotherapy in Pulmonary Arterial Hypertension With Cardiovascular comorbiDITIES

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension: a Randomized, Double-blind, Placebo-controlled Trial

Phase 4 · Recruiting · Beijing Anzhen Hospital

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Phase 3 · Recruiting · Inhibikase Therapeutics
Recently completed

A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients

Phase 4 · Completed · Boryung Pharmaceutical Co., Ltd

A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy.

Phase 3 · Completed · LG Life Sciences

An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg Plus Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination in Patients With Hypertension

Phase 3 · Completed · Boehringer Ingelheim

An Open-label Study to Evaluate the Antihypertensive Effects of the Fixed-dose Combination of Telmisartan 80 mg and Amlodipine 5 mg (T80/A5) Given Once Daily by 24 h ABPM in Patients With Moderate to Severe Hypertension

Phase 3 · Completed · Boehringer Ingelheim

An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With the Single Pill (SPC) Combination of Aliskiren 300 mg / Amlodipine 10 mg in Hypertensive Patients Not Adequately Respond to an Uptitrated 4 Week Therapy With the SPC of Olmesartan 40 mg / Amlodipine 10 mg, With a Potential Extension if Patients Still Not Adequately Respond With a 4 Week Therapy With the SPC Aliskiren 300 mg / Amlodipine 10 mg / HCTZ 12,5 mg

Phase 3 · Completed · Novartis

Evidence coverage

8 treatments

How much of this condition's readable clinical evidence the confidence engine has incorporated, across its most-studied treatments. This measures coverage of the evidence base — not whether any treatment works.

Substantial evidence coverage
66% · 73/111 eligible items incorporated
lowers systolic blood pressure in hypertension65%
lowers diastolic blood pressure in hypertension65%

Largest gap: no meaningful change (9, trial-readability).

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
2023emaOriginal application approval — Spironolactone· In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). source ↗
2011emaOriginal application approval — Azilsartan medoxomil· Edarbi is indicated for the treatment of essential hypertension in adults. source ↗
2010emaGeneric approval — Telmisartan· Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type 2 diabetes mellitus with documented target organ damage. source ↗
2010emaGeneric approval — Telmisartan· Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or; type 2 diabetes mellitus with documented target organ damage. source ↗
2009emaGeneric approval — Irbesartan· Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen. source ↗
2007emaOriginal application approval — Aliskiren· Treatment of essential hypertension. source ↗
2007emaOriginal application approval — Irbesartan· Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen. source ↗
1998emaOriginal application approval — Telmisartan· Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage. source ↗
Other regulatory activity
2026emaProduct authorisation ended — Telmisartan· Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage. source ↗
2026emaProduct authorisation ended — Telmisartan· Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 paper

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Gut microbiota dysbiosis contributes to the development of hypertension.

Microbiome · 2017 · 1,229 cites
Recent publications

Gut microbiota dysbiosis contributes to the development of hypertension.

Microbiome · 2017 · 1,229 cites
Major themes1
  • Fecal Microbiota Transplantation1
Leading journals1
  • Microbiome1
Leading researchers8
  • Auguste K1
  • Cai J1
  • Chen J1
  • Chen L1
  • Cui Q1
  • Geng B1
  • Li J1
  • Liu W1
Affiliations (unnormalised)6
  • Baoding NO.1 Central Hospital1
  • Beijing ChaoYang Hospital1
  • Beijing Key Laboratory of Hypertension1
  • CAS Key Laboratory of Pathogenic Microbiology and Immunology1
  • Centre for Noncoding RNA Medicine1
  • Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

AGTR10.72AGT0.63ENPEP0.58DBH0.57UMOD0.55FGF50.54FBN20.53SWAP700.52ZC3HC10.51SOS20.51FURIN0.50ARHGAP420.50

Disease biology

9 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Type-1 angiotensin II receptorvia AGTR10.72Beta-nerve growth factorvia NGF0.48Potassium channel subfamily K member 3via KCNK30.46Reninvia REN0.43Calcitonin gene-related peptide type 1 receptorvia CALCRL0.41Tyrosine-protein kinase HCKvia HCK0.38Platelet endothelial cell adhesion moleculevia PECAM10.25Tyrosine-protein kinase CSKvia CSK0.23Proto-oncogene Masvia MAS10.22

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Hypertension that occurs without known cause, or preexisting renal disease. Associated polymorphisms for a number of genes have been identified, including AGT, GNB3, and ECE1. OMIM: 145500

Identifiers
MeSHEssential Hypertension
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.